196 related articles for article (PubMed ID: 16131837)
1. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
Luo J; Cantley LC
Cell Cycle; 2005 Oct; 4(10):1309-12. PubMed ID: 16131837
[TBL] [Abstract][Full Text] [Related]
2. Class IA PI3K regulatory subunits: p110-independent roles and structures.
Fox M; Mott HR; Owen D
Biochem Soc Trans; 2020 Aug; 48(4):1397-1417. PubMed ID: 32677674
[TBL] [Abstract][Full Text] [Related]
3. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Chagpar RB; Links PH; Pastor MC; Furber LA; Hawrysh AD; Chamberlain MD; Anderson DH
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5471-6. PubMed ID: 20212113
[TBL] [Abstract][Full Text] [Related]
4. The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex.
Luo J; Field SJ; Lee JY; Engelman JA; Cantley LC
J Cell Biol; 2005 Aug; 170(3):455-64. PubMed ID: 16043515
[TBL] [Abstract][Full Text] [Related]
5. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.
Geering B; Cutillas PR; Nock G; Gharbi SI; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2007 May; 104(19):7809-14. PubMed ID: 17470792
[TBL] [Abstract][Full Text] [Related]
6. Interaction of the retinal insulin receptor beta-subunit with the p85 subunit of phosphoinositide 3-kinase.
Rajala RV; McClellan ME; Chan MD; Tsiokas L; Anderson RE
Biochemistry; 2004 May; 43(19):5637-50. PubMed ID: 15134438
[TBL] [Abstract][Full Text] [Related]
7. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
8. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras.
Jimenez C; Hernandez C; Pimentel B; Carrera AC
J Biol Chem; 2002 Nov; 277(44):41556-62. PubMed ID: 12196526
[TBL] [Abstract][Full Text] [Related]
9. Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase.
Kessler A; Uphues I; Ouwens DM; Till M; Eckel J
Am J Physiol Endocrinol Metab; 2001 Jan; 280(1):E65-74. PubMed ID: 11120660
[TBL] [Abstract][Full Text] [Related]
10. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits?
Geering B; Cutillas PR; Vanhaesebroeck B
Biochem Soc Trans; 2007 Apr; 35(Pt 2):199-203. PubMed ID: 17371237
[TBL] [Abstract][Full Text] [Related]
11. The inhibition of p85αPI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells.
Feola A; Cimini A; Migliucci F; Iorio R; Zuchegna C; Rothenberger R; Cito L; Porcellini A; Unteregger G; Tombolini V; Giordano A; Di Domenico M
J Cell Biochem; 2013 Sep; 114(9):2114-9. PubMed ID: 23553770
[TBL] [Abstract][Full Text] [Related]
12. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival.
Ueki K; Fruman DA; Brachmann SM; Tseng YH; Cantley LC; Kahn CR
Mol Cell Biol; 2002 Feb; 22(3):965-77. PubMed ID: 11784871
[TBL] [Abstract][Full Text] [Related]
13. BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity.
Chiu YH; Lee JY; Cantley LC
Mol Cell; 2014 Apr; 54(1):193-202. PubMed ID: 24657164
[TBL] [Abstract][Full Text] [Related]
14. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.
Zhao L; Vogt PK
Cell Cycle; 2010 Feb; 9(3):596-600. PubMed ID: 20009532
[TBL] [Abstract][Full Text] [Related]
15. LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85.
Xu S; Li Y; Lu Y; Huang J; Ren J; Zhang S; Yin Z; Huang K; Wu G; Yang K
Cancer Lett; 2018 Apr; 420():38-48. PubMed ID: 29409973
[TBL] [Abstract][Full Text] [Related]
16. Human tumor mutants in the p110alpha subunit of PI3K.
Liu Z; Roberts TM
Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
[TBL] [Abstract][Full Text] [Related]
17. Synergistic activation of a family of phosphoinositide 3-kinase via G-protein coupled and tyrosine kinase-related receptors.
Katada T; Kurosu H; Okada T; Suzuki T; Tsujimoto N; Takasuga S; Kontani K; Hazeki O; Ui M
Chem Phys Lipids; 1999 Apr; 98(1-2):79-86. PubMed ID: 10358930
[TBL] [Abstract][Full Text] [Related]
18. Recruitment of the tyrosine phosphatase Src homology 2 domain tyrosine phosphatase-2 to the p85 subunit of phosphatidylinositol-3 (PI-3) kinase is required for insulin-like growth factor-I-dependent PI-3 kinase activation in smooth muscle cells.
Kwon M; Ling Y; Maile LA; Badley-Clark J; Clemmons DR
Endocrinology; 2006 Mar; 147(3):1458-65. PubMed ID: 16306077
[TBL] [Abstract][Full Text] [Related]
19. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases.
Vadas O; Burke JE; Zhang X; Berndt A; Williams RL
Sci Signal; 2011 Oct; 4(195):re2. PubMed ID: 22009150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
